Preparation of oxymatrine n-butyl polycyanoacrylate nanoparticles and its hepatoprotective effects in ob/ob mice

This study aims to prepare oxymatrine n-butyl polycyanoacrylate nanoparticles (OM-PBCA-NPs) and observe its hepatoprotective effects in ob/ob mice.Using oxymatrine as the drug and n-butyl cyanoacrylate (BCA) as the carrier to prepare OM-PBCA-NPs by the emulsion polymerization method; ob/ob mice were used as the mouse model of liver injury, given OM-PBCA-NPs, and collected the blood at the end of Week 12 of the experiment to detect the blood lipids, serum alanine aminotransferase (ALT), and aspartate aminotransferase (AST).Under SEM, the particles of OM-PBCA-NPs were round and well-formed with no adhesion.The average particle size was (104.1 ± 29.11) nm, the distribution was narrow, and the particle size met the requirements of particle size for liver targeted therapy.The encapsulation efficiency was 83% and the drug load amount was 16.6%.Moreover, OM-PBCA-NPs can significantly reduce the blood lipid level and serum ALT/AST contents in mice with fatty liver injury, and its effects were better than common oxymatrine granules.OM-PBCA-NPs has good liver targeting effects, and its hepatoprotective and lipid-lowering effects are superior to those of common oxymatrine granules.